DaVita Inc/ US23918K1088 /
11/27/2023 9:59:55 PM | Chg. +0.22 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
99.43USD | +0.22% | 52,303 Turnover: 5.21 mill. |
-Bid Size: - | -Ask Size: - | 9.07 bill.USD | - | 16.48 |
GlobeNewswire
3/21/2022
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
GlobeNewswire
3/7/2022
The Oncology Institute Announces Promotions for Dr. Daniel Virnich and Dr. Matt Miller
GlobeNewswire
2/10/2022
Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022
GlobeNewswire
10/7/2021
Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Anima...
GlobeNewswire
10/1/2021
AAON Increases Board Size and Appoints Bruce Ware and David Stewart as Independent Directors
GlobeNewswire
9/9/2021
ACTION BEHAVIOR CENTERS HIRES NEW GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
GlobeNewswire
9/9/2021
Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development
GlobeNewswire
8/11/2021
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and ...
GlobeNewswire
8/3/2021
Qualis Innovations Inc. Announces the Appointment of Skip Thurman as Sr. Vice President, Corporate a...
GlobeNewswire
6/7/2021
Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyInte...
GlobeNewswire
6/2/2021
Vystar Partners with “Nothing in the Air” for RxAir Marketing, Advertising & Distribution
GlobeNewswire
1/5/2021
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
GlobeNewswire
11/10/2020
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results